Published online Dec 16, 2021. doi: 10.4253/wjge.v13.i12.649
Peer-review started: May 26, 2021
First decision: June 17, 2021
Revised: June 22, 2021
Accepted: June 28, 2021
Article in press: June 28, 2021
Published online: December 16, 2021
Processing time: 201 Days and 17 Hours
Intra-abdominal lymphadenopathy due to tuberculosis (TB) poses a diagnostic challenge due to difficulty in tissue acquisition.
Endoscopic ultrasound guided fine needle aspiration/biopsy (EUS-FNA/B) has shown excellent results in patients with mediastinal lymphadenopathy. However, its role in the evaluation of abdominal lymphadenopathy due to TB needs further clarity.
The utility of EUS-FNA/B in the evaluation of intra-abdominal lymphadenopathy was assessed by evaluating the diagnostic yield in patients with confirmed TB.
This was a single center retrospective study conducted in a large tertiary care hospital where patients with intra-abdominal lymphadenopathy referred for EUS-FNA/B were studied. The diagnosis of TB was confirmed and EUS-FNA/B results including cytology, pathological diagnosis, ancillary test findings (TB culture, GeneXpert) and demographics in these patients were carefully analyzed.
This study showed that EUS-FNA/B has a high diagnostic yield with good sensitivity (86%), specificity (93%) and diagnostic accuracy (88%) in the evaluation of intra-abdominal lymphadenopathy in patients with a clinical suspicion of TB. Morphological findings on EUS evaluation of intra-abdominal lymphadenopathy include hypoechoic/heteroechoic nodes, with sharp borders, with/without matting.
EUS-FNA/B is a viable, reliable and safe procedure, which can be performed with moderate sedation and can potentially prevent further invasive testing in this subgroup of patients.
This study provides vital information that can guide the approach and management of patients with intra-abdominal lymphadenopathy. A management algorithm that highlights key points during the management of these patients is provided. However, the utility of this procedure in populations with a low prevalence of TB needs more clarity. In addition, a protocol-based approach with additional tests such as TB culture, acid fast bacilli stain, TB-polymerase chain reaction or GeneXpert in specific subgroups of patients at risk for TB needs to be developed and evaluated in future studies.
